2 Stocks To Watch Today Following Clinical Trial Updates

Lexeo Therapeutics, Inc. (LXEO), a clinical-stage genetic medicine company pioneering novel treatments for cardiovascular diseases, has finalized the pivotal study design for gene therapy candidate LX2006 in Friedreich Ataxia.